Research Topics
| Barry A GustersonSummaryAffiliation: University of Glasgow Country: UK Publications
| Collaborators
|
Detail Information
Publications
Mammary gland involution as a multi-step processTorsten Stein
Division of Cancer Sciences and Molecular Pathology, Section of Gene Regulation and Mechanisms of Disease, Western Infirmary, University of Glasgow, Glasgow G11 6NT, UK
J Mammary Gland Biol Neoplasia 12:25-35. 2007..This review provides a synthesis of published data, integrating the time course of transcriptional activity in the mouse mammary gland with a gene ontology approach to identify the pathways involved...- Should we be surprised at the paucity of response to EGFR inhibitors?Barry A Gusterson
Department of Pathology, Division of Cancer Sciences and Molecular Pathology, Faculty of Medicine, University of Glasgow, Western Infirmary, Glasgow, UK
Lancet Oncol 10:522-7. 2009..However, we still have a lot to learn about this receptor, its many ligands, and its binding partners in normal physiology and disease... - Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancerBarry A Gusterson
Division of Cancer Sciences and Molecular Pathology, Western Infirmary, University of Glasgow, Glasgow, UK
Breast Cancer Res 7:143-8. 2005..This article reviews the lineages in the normal breast in relation to what have become known as the 'basal-like' carcinomas... - Involvement of axonal guidance proteins and their signaling partners in the developing mouse mammary glandJoanna S Morris
Division of Cancer Sciences and Molecular Pathology, University of Glasgow, Department of Pathology, Western Infirmary, Glasgow, Scotland, United Kingdom
J Cell Physiol 206:16-24. 2006..We suggest that these genes may influence ductal growth and morphogenesis in the developing mammary gland... - Proteomic analysis of the mouse mammary gland is a powerful tool to identify novel proteins that are differentially expressed during mammary developmentClaire R Davies
Department of Pathology, Division of Cancer Sciences and Molecular Pathology, Glasgow, Scotland, UK
Proteomics 6:5694-704. 2006..MCM3 expression during lactation may identify cells that are licensed to repopulate the gland during cell loss in lactation and following involution... - A mouse mammary gland involution mRNA signature identifies biological pathways potentially associated with breast cancer metastasisTorsten Stein
Division of Cancer Sciences and Molecular Pathology, Section of Gene Regulation and Mechanisms of Disease, Western Infirmary, University of Glasgow, Glasgow, UK
J Mammary Gland Biol Neoplasia 14:99-116. 2009.... - Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancerTorsten Stein
Division of Cancer Sciences and Molecular Pathology, Western Infirmary, Glasgow, United Kingdom
Clin Cancer Res 11:6872-9. 2005..We assessed Annexin A8's contribution to the overall prognosis and its expression in normal, benign, and cancerous tissue and addressed Annexin A8's physiologic role in the mammary gland... - Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosisTorsten Stein
Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, Department of Pathology, Western Infirmary, University of Glasgow, Glasgow, G11 6NT, UK
Am J Pathol 177:2323-33. 2010..We conclude that reelin may play an important role in controlling invasiveness and metastatic potential of breast cancer cells and that its expression is controlled by promoter methylation... - Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3Torsten Stein
Division of Cancer Sciences and Molecular Pathology, Western Infirmary, Glasgow, UK
Breast Cancer Res 6:R75-91. 2004..Involution of the mammary gland is a complex process of controlled apoptosis and tissue remodelling. The aim of the project was to identify genes that are specifically involved in this process... - Proteomic analysis of mouse mammary terminal end buds identifies axonal growth cone proteinsJoanna S Morris
University of Glasgow, Division of Cancer Sciences and Molecular Pathology, Department of Pathology, Western Infirmary, Glasgow, Scotland
Proteomics 4:1802-10. 2004.... - A prophylactic vaccine for breast cancer?Christine J Watson
Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, UK
Breast Cancer Res 12:310. 2010..This also showed some efficacy as a therapeutic vaccine. Can we look forward to the elimination of breast cancer?.. - Development of novel selective cell ablation in the mammary gland and brain to study cell-cell interactions and chemopreventionBarry A Gusterson
Department of Pathology, Western Infirmary, Glasgow G11 6NT, UK
Recent Results Cancer Res 163:31-45; discussion 264-6. 2003..The results clearly demonstrate that the model has potential to study chemoprevention and fundamental questions on cell-cell interactions in cell biology... - Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?Helen Trihia
International Breast Cancer Study Group Pathology Center, Western Infirmary, Glasgow, United Kingdom
Cancer 97:1321-31. 2003..When it is used alone, Ki-67 detection provides valuable information, although it is necessary to combine this with other parameters in the study of core biopsies and fine-needle aspirates... - LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situArmine Baltayan
Department of Pathology, USC Keck School of Medicine, Los Angeles, CA, USA
Anticancer Res 22:2933-7. 2002..41 +/- 0.10) and 10 years (0.63 +/- 0.12). The results of this pilot study show that LEA.135 expression is significantly associated with a favorable prognosis of patients with DCIS, leading to a decreased incidence of recurrence... - Inhibition of myc-dependent breast tumor formation in transgenic miceWei Cui
Department of Gene Expression and Development, Roslin Institute, Midlothian, UK
Breast Cancer Res Treat 71:9-20. 2002..Our results suggest that the enzyme pro-drug system NTR-CB1954 efficiently inhibit myc-dependent tumor formation and malignant progression in the mammary gland... - Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trialsBernhard C Pestalozzi
Department of Oncology, University Hospital, Raemistrasse 100, 8091 Zurich, Switzerland
J Clin Oncol 26:3006-14. 2008..To determine how patients with infiltrating lobular carcinoma (ILC) differ from patients with the more common infiltrating ductal carcinoma (IDC) with regard to patient and tumor factors, local treatment, and patterns of recurrence... - Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study GroupGiuseppe Viale
Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
J Clin Oncol 26:1404-10. 2008.... - Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancerGiuseppe Viale
Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Via Ripamoniti 435, Milan, Italy
J Natl Cancer Inst 100:207-12. 2008..Thus, Ki-67 labeling index was an independent prognostic factor but was not predictive of better response to adjuvant chemotherapy in these studies... - Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trialBirgitte B Rasmussen
Department of Pathology, Nordsjaellands Hospital, Hilleroed, Denmark
Lancet Oncol 9:23-8. 2008..Our aim was to establish whether the benefit of letrozole versus tamoxifen differs according to the ERBB2 status of tumours... - Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98Giuseppe Viale
Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
J Clin Oncol 25:3846-52. 2007..To evaluate locally versus centrally assessed estrogen (ER) and progesterone (PgR) receptor status and the impact of PgR on letrozole adjuvant therapy compared with tamoxifen in postmenopausal women with early breast cancer... - The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancerPer Karlsson
Department of Oncology, University of Goteborg, Sahlgrenska University Hospital, Goteborg, Sweden
J Clin Oncol 25:2019-26. 2007..To identify groups of early breast cancer patients with substantial risk (10-year risk > 20%) for locoregional failure (LRF) who might benefit from postmastectomy radiotherapy (RT)... - Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from IVito J Spataro
Department of Medical Oncology, Ospedale San Giovanni, Bellinzona, Switzerland
Cancer 97:1591-600. 2003.... - Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotypeSunil R Lakhani
The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
Clin Cancer Res 11:5175-80. 2005..To investigate the proportion of breast cancers arising in patients with germ line BRCA1 and BRCA2 mutations expressing basal markers and developing predictive tests for identification of high-risk patients... - Concomitant inactivation of p53 and Chk2 in breast cancerAlexandra Sullivan
Ludwig Institute for Cancer Research, Imperial College Faculty of Medicine, St Mary's Campus, Norfolk Place, London W2 1PG, UK
Oncogene 21:1316-24. 2002..However, consistent with other studies, we show that germ-line mutations in Chk2 are unlikely to account for a significant proportion of non BRCA1-, non BRCA2-associated hereditary breast cancers...